Just got this info from the Clinical Islet Transplantation (CIT) Consortium:
The following studies are dedicated to moving the field forward with innovative approaches to islet transplantation.
-
CIT-07 “Islet Transplantation in Type 1 Diabetes”: all North American sites
-
CIT-06 “Efficacy of Islet After Kidney Transplantation”: all North American sites
-
CIT-01A /01B (Islet Alone/Islet After Kidney) “Safety and Efficacy of Low Molecular Weight Dextran Sulfate (LMW-DS) in Islet Transplantation”:
Uppsala University Hospital (Uppsala, Sweden) Karolinska University Hospital (Stockholm, Sweden, and University Hospital Rikshospitalet (Oslo, Norway) -
CIT-02 “Strategies to Improve Long-term Islet Graft Survival”:
University of Miami (Miami, Florida) and University of Illinois at Chicago (Chicago, Illinois) -
CIT-03 “Peritransplantation Deoxyspergualin in Islet Transplantation”:
University of Minnesota (Minneapolis, Minnesota), Northwestern University (Chicago, Illinois), and University of California (San Francisco, California) -
CIT-04 “Islet Transplantation with Belatacept”:
University of Alberta, Edmonton (Edmonton, Alberta) and Emory University (Atlanta, Georgia) -
CIT-05 “B-Lymphocyte Immunotherapy in Islet Transplantation”:
University of Pennsylvania (Philadelphia, Pennsylvania)
More detailed study-specific information can be found on the CIT Consortium web site at www.citisletstudy.org .
Please contact Tracy (contact info below) if you would like brochures mailed to you or if you would like the contact information for a CIT Consortium study site:
Traci Ripperda, MA, CCRA
Protocol Coordinator
Clinical Trials Data Management Center
2400 UCC
Iowa City, IA 52242
Ph: 319-384-4180
Fax: 319-353-3960